Cardiovascular Drugs Practice Questions

Q: Prolonged administration of sodium nitroprusside can cause poisoning of which substance?

Cyanide. Explanation: Sodium Nitroprusside (SNP) is a potent, rapid-acting vasodilator used in hypertensive emergencies [1]. Its chemical structure consists of a ferrous iron center surrounded by five cyanide (CN⁻) groups and one nitrosyl group. Why Cyanide is the correct answer: When SNP is administered intravenously, it reacts with hemoglobin and sulfhydryl groups in erythrocytes to release nitric oxide (the active vasodilator) and five cyanide ions. Normally, the liver enzyme rhodanese detoxifies cyanide by converting it into thiocyanate using sulfur donors (thiosulfate) [2]. However, with prolonged infusion (typically >24–48 hours) or high doses, the body’s thiosulfate stores are exhausted. This leads to cyanide accumulation, which inhibits mitochondrial cytochrome oxidase, causing cellular hypoxia and lactic acidosis. Why other options are incorrect: Methanol: Poisoning typically occurs via ingestion of adulterated alcohol, leading to formic acid accumulation. It is not a byproduct of SNP metabolism. Arsenic: A heavy metal toxin that inhibits pyruvate dehydrogenase; it is unrelated to vasodilator therapy. Phenol: Used as a disinfectant or chemical intermediate; it is not chemically related to the structure or metabolism of nitroprusside. High-Yield Clinical Pearls for NEET-PG: Early sign of toxicity: Metabolic acidosis (due to lactate) and an unexplained decrease in oxygen saturation (venous hyperoxemia). Management of SNP-induced Cyanide Poisoning: 1. Sodium Thiosulfate: Provides sulfur donors for rhodanese [2]. 2. Hydroxocobalamin (Vitamin B12a): Binds cyanide to form non-toxic cyanocobalamin (preferred first-line) [2]. 3. Amyl/Sodium Nitrite: Induces methemoglobinemia, which has a high affinity for cyanide [2]. Thiocyanate Toxicity: In patients with renal failure, the metabolite thiocyanate can accumulate, causing psychosis and seizures.

Q: What is the therapeutic plasma level of digoxin?

0.8-1.5 ng/ml. **Explanation:** Digoxin is a cardiac glycoside with a **narrow therapeutic index**, meaning the margin between a therapeutic dose and a toxic dose is very small [1]. Monitoring serum drug concentrations is critical for safety and efficacy. 1. **Why Option B is Correct:** The established therapeutic range for digoxin is generally **0.8–1.5 ng/ml** (some texts suggest 0.5–2.0 ng/ml). Within this range, the drug effectively increases vagal tone and inhibits the Na+/K+-ATPase pump to improve cardiac contractility and control ventricular rate in atrial fibrillation without causing significant toxicity [1], [2]. 2. **Why Other Options are Incorrect:** * **Option A (0.1–0.3 ng/ml):** This level is sub-therapeutic and will not provide the desired clinical effect. * **Option C (1.2–2 ng/ml):** While some patients may tolerate up to 2.0 ng/ml, levels above 1.5 ng/ml significantly increase the risk of toxicity, especially in patients with electrolyte imbalances [1], [2]. * **Option D (>2.4 ng/ml):** This is well into the **toxic range**. Digoxin toxicity typically manifests at levels >2.0 ng/ml [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Toxicity Trigger:** Hypokalemia (low potassium) predisposes a patient to digoxin toxicity even if serum levels are within the "normal" range because potassium competes with digoxin for the Na+/K+-ATPase binding site. * **Antidote:** Digoxin-specific antibody fragments (**DigiFab/Digibind**) are used for life-threatening toxicity. * **ECG Changes:** The most common sign of toxicity is **PVCs** (Premature Ventricular Contractions); the most characteristic sign is **Paroxysmal Atrial Tachycardia with AV block** [3]. * **Visual Disturbance:** Xanthopsia (yellow-green vision) is a classic sign of digitalis toxicity.

Q: Valsartan differs from ramipril in the following respect?

It does not potentiate bradykinin. **Explanation:** The core difference between **Valsartan** (an Angiotensin Receptor Blocker - ARB) and **Ramipril** (an ACE Inhibitor) lies in their mechanism of action regarding the kinin system. **1. Why Option A is correct:** ACE (Angiotensin-Converting Enzyme) is identical to **Kininase II**, the enzyme responsible for the degradation of **bradykinin**. * **Ramipril (ACEI):** Inhibits Kininase II, leading to increased levels of bradykinin. This accumulation is responsible for the classic side effects of dry cough and angioedema. * **Valsartan (ARB):** Directly blocks the $AT_1$ receptor without affecting the ACE enzyme. Therefore, it **does not potentiate bradykinin**, making it a preferred alternative for patients who develop a cough on ACE inhibitors. **2. Why other options are incorrect:** * **Option B:** Both ACEIs and ARBs are **contraindicated** in bilateral renal artery stenosis. They prevent $AT_2$-mediated vasoconstriction of the efferent arteriole, which can lead to a precipitous drop in GFR and acute renal failure. * **Option C:** Neither drug impairs carbohydrate tolerance. In fact, both classes are known to **improve insulin sensitivity** and are the drugs of choice for hypertensive diabetic patients due to their nephroprotective effects. * **Option D:** Both ACEIs and ARBs are **teratogenic** (Category X). They have significant fetopathic potential, causing fetal renal anomalies, oligohydramnios, and skull hypoplasia. **Clinical Pearls for NEET-PG:** * **Dry Cough:** Occurs in ~10-15% of patients on ACEIs due to bradykinin and substance P accumulation in the lungs. * **First-line choice:** Both classes are first-line for Heart Failure (reduce remodeling) and Diabetic Nephropathy (reduce proteinuria). * **Hyperkalemia:** Both classes can cause hyperkalemia; monitor potassium levels closely.

Q: Which beta-blocker possesses peripheral vasodilator action?

Carvedilol. The correct answer is **Carvedilol**. Beta-blockers are classified into three generations based on their pharmacological properties. [1] Carvedilol is a **third-generation, non-selective beta-blocker** that also possesses **alpha-1 ($\alpha_1$) adrenergic receptor blocking activity**. [3] This dual action results in peripheral vasodilation, which reduces systemic vascular resistance and afterload. [1, 3] **Why the correct option is right:** * **Carvedilol:** By blocking $\beta_1$, $\beta_2$, and $\alpha_1$ receptors, it provides both cardiac protection and vasodilation. [3] It also possesses antioxidant and anti-proliferative properties, making it a cornerstone in the management of chronic heart failure. **Why the other options are incorrect:** * **Propranolol (Option A):** A first-generation, non-selective beta-blocker. [2] It lacks $\alpha$-blocking activity and may actually cause transient peripheral vasoconstriction due to unopposed $\alpha$-action when $\beta_2$ receptors are blocked. * **Atenolol (Option B):** A second-generation, cardioselective ($\beta_1$) blocker. It does not have vasodilatory properties. * **Acebutolol (Option D):** A second-generation, cardioselective blocker with **Intrinsic Sympathomimetic Activity (ISA)**. While it causes less bradycardia, it is not a direct peripheral vasodilator. **High-Yield Clinical Pearls for NEET-PG:** * **Third-Generation Vasodilatory Beta-blockers:** [1] * **Via $\alpha_1$ blockade:** Carvedilol, Labetalol. [3] * **Via Nitric Oxide (NO) release:** Nebivolol (most $\beta_1$ selective). * **Via $\beta_2$ agonism:** Celiprolol. * **Labetalol** is the drug of choice for hypertension in pregnancy (Preeclampsia). [1]

Q: All of the following can be used for the chronic oral treatment of arrhythmia except?

Esmolol. **Explanation:** The correct answer is **Esmolol** because of its unique pharmacokinetic profile. In the management of arrhythmias, the choice between oral and parenteral therapy depends on whether the goal is acute termination or chronic prophylaxis. **1. Why Esmolol is the correct answer:** Esmolol is an **ultra-short-acting**, cardioselective $\beta_1$ blocker. It is rapidly metabolized by **red blood cell esterases**, giving it an extremely short half-life of approximately **9 minutes**. Due to this rapid metabolism and its susceptibility to gastric acid, it cannot be administered orally. It is given exclusively via intravenous infusion for the acute management of supraventricular tachycardias (SVT), perioperative hypertension, or atrial fibrillation/flutter where rapid control is required. **2. Analysis of Incorrect Options:** * **Amiodarone (Class III):** Has a very long half-life (weeks to months) and is frequently used orally for the chronic maintenance of sinus rhythm in patients with atrial fibrillation or ventricular arrhythmias. * **Quinidine (Class IA):** An alkaloid that can be administered orally for the long-term prevention of SVT and ventricular tachycardia (though its use is declining due to side effects). * **Verapamil (Class IV):** A non-dihydropyridine calcium channel blocker available in oral formulations for the chronic rate control of atrial fibrillation and prevention of paroxysmal SVT. **Clinical Pearls for NEET-PG:** * **Esmolol "Rule of 9":** Half-life is ~9 minutes; full recovery from its effects occurs within ~20-30 minutes of stopping the infusion. * **Drug of Choice:** Esmolol is the preferred $\beta$-blocker for **Aortic Dissection** and **Thyroid Storm** during surgery due to its titratability. * **Safety:** Because of its short duration, if a patient develops bradycardia or hypotension, simply stopping the infusion resolves the side effects quickly.

Q: Which of the following is NOT a Class III antiarrhythmic agent?

Verapamil. **Explanation:** The classification of antiarrhythmic drugs is based on the **Vaughan-Williams classification**, which categorizes agents according to their primary mechanism of action on the cardiac action potential. **Why Verapamil is the correct answer:** Verapamil is a **Class IV antiarrhythmic agent**. Its primary mechanism is the blockade of L-type voltage-gated calcium channels. It acts predominantly on the SA and AV nodes, slowing conduction and prolonging the refractory period. It is used primarily for supraventricular tachycardias (SVT) and rate control in atrial fibrillation. **Analysis of Class III Agents (Incorrect Options):** Class III agents are **Potassium (K+) channel blockers**. They prolong Phase 3 repolarization, thereby increasing the Action Potential Duration (APD) and the Effective Refractory Period (ERP). * **Sotalol:** A unique agent with both non-selective beta-blocking (Class II) and K+ channel blocking (Class III) properties. * **Amiodarone:** A broad-spectrum agent that exhibits properties of all four Vaughan-Williams classes but is primarily categorized as Class III. * **Bretylium:** An older Class III agent (also a post-ganglionic adrenergic blocker) used historically for refractory ventricular fibrillation. **High-Yield NEET-PG Pearls:** * **Mnemonic for Class III:** "**A**id **I**s **D**octor **S**otalol" (**A**miodarone, **I**butilide, **D**ofetilide, **S**otalol). * **Amiodarone** contains iodine and is associated with pulmonary fibrosis, thyroid dysfunction (hypo/hyper), and corneal microdeposits. * **Reverse Use-Dependence:** A characteristic of Class III drugs (except Amiodarone) where their effect is more pronounced at slower heart rates, increasing the risk of **Torsades de Pointes**.

Q: Enalapril increases the level of which of the following?

Bradykinin. ### Explanation **Correct Option: C (Bradykinin)** **Mechanism:** Enalapril is an **Angiotensin-Converting Enzyme (ACE) Inhibitor**. The ACE enzyme (also known as Kininase II) has a dual function in the body: 1. It converts Angiotensin I to Angiotensin II (a potent vasoconstrictor). 2. It degrades **Bradykinin** (a potent vasodilator) into inactive metabolites. By inhibiting ACE, Enalapril prevents the breakdown of Bradykinin, leading to its accumulation in the tissues and blood. **Why the other options are incorrect:** * **A & B (Interferon and Growth factors):** ACE inhibitors do not have a direct or clinically significant effect on the systemic levels of interferons or growth factors. While ACE inhibitors may indirectly influence tissue remodeling (e.g., reducing cardiac hypertrophy), they do not "increase" these specific molecules as a primary pharmacological action. --- ### High-Yield Clinical Pearls for NEET-PG: * **The "Dry Cough" Connection:** The accumulation of Bradykinin and Substance P in the lungs is the primary cause of the characteristic **dry, hacking cough** seen in 5–20% of patients on ACE inhibitors. * **Angioedema:** Increased Bradykinin levels are also responsible for the rare but life-threatening side effect of angioedema. * **Switching Therapy:** If a patient develops a cough due to Enalapril, the best next step is to switch them to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not inhibit Kininase II and thus do not increase Bradykinin. * **Active Form:** Remember that Enalapril is a **prodrug**; it must be converted by hepatic esterases into its active metabolite, **Enalaprilat**. (Lisinopril and Captopril are the exceptions—they are not prodrugs).

Q: Which of the following statements about Esmolol is true?

It is used in left ventricular decompensation.. **Explanation:** **Esmolol** is a unique, ultra-short-acting **beta-1 selective (cardioselective) blocker**. **Why Option D is Correct:** While beta-blockers are generally contraindicated in acute heart failure, Esmolol is specifically indicated for the management of **supraventricular tachyarrhythmias** or hypertension in patients with **left ventricular decompensation** (acute heart failure) or perioperative settings. Its "safety net" lies in its ultra-short duration of action; if the patient’s cardiac output drops further, the drug effect disappears within minutes of stopping the infusion, allowing for precise titration. **Analysis of Incorrect Options:** * **Option A:** Esmolol is a **Beta-blocker**, not an alpha-blocker. * **Option B:** It has an **extremely short half-life** (approximately 9 minutes). This is because it is rapidly hydrolyzed by **red blood cell esterases** (not by liver or kidney enzymes). * **Option C:** It is highly **cardioselective** (Beta-1 selective), making it safer for patients with reactive airway disease compared to non-selective blockers like Propranolol. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** Always given **Intravenously (IV)**; never orally. * **Metabolism:** Hydrolysis by RBC esterases (Unique feature). * **Indications:** Aortic dissection (to reduce shear stress), Thyroid storm, and perioperative tachycardia/hypertension. * **Mnemonic:** Remember **"Esmolol is Easy-off"** due to its rapid offset of action.

Question 1

Tachycardia due to nitrates in a patient with angina pectoris is blocked by which of the following drug classes?

Accepted Answer

Beta blocker

Answer

Digoxin

Answer

Dobutamine

Answer

Calcium channel blocker

Question 2

Prolonged administration of sodium nitroprusside can cause poisoning of which substance?

Accepted Answer

Cyanide

Answer

Methanol

Answer

Arsenic

Answer

Phenol

Question 3

What is the therapeutic plasma level of digoxin?

Accepted Answer

0.8-1.5 ng/ml

Answer

0.1-0.3 ng/ml

Answer

1.2-2 ng/ml

Answer

More than 2.4 ng/ml

Question 4

Valsartan differs from ramipril in the following respect?

Accepted Answer

It does not potentiate bradykinin

Answer

It can be safely administered to a patient with bilateral renal artery stenosis

Answer

It impairs carbohydrate tolerance

Answer

It does not have fetopathic potential

Question 5

Which beta-blocker possesses peripheral vasodilator action?

Accepted Answer

Carvedilol

Answer

Propranolol

Answer

Atenolol

Answer

Acebutolol

Question 6

All of the following can be used for the chronic oral treatment of arrhythmia except?

Accepted Answer

Esmolol

Answer

Amiodarone

Answer

Quinidine

Answer

Verapamil

Question 7

Which of the following is NOT a Class III antiarrhythmic agent?

Accepted Answer

Verapamil

Answer

Sotalol

Answer

Amiodarone

Answer

Bretylium

Question 8

Enalapril increases the level of which of the following?

Accepted Answer

Bradykinin

Answer

Interferon

Answer

Growth factors

Answer

All of the above

Question 9

Which of the following statements about Esmolol is true?

Accepted Answer

It is used in left ventricular decompensation.

Answer

It is an alpha blocker.

Answer

It has a long half-life.

Answer

It is not cardioselective.

Question 10

Which of the following statements regarding ACE inhibitors is TRUE?

Accepted Answer

Omission of prior diuretic dose decreases the risk of postural hypotension

Answer

These inhibit the conversion of angiotensinogen to angiotensin I

Answer

Lisinopril is shorter acting than enalapril

Answer

These are contraindicated in diabetic patients.

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?